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Abstract
Background: Current population surveys suggest around 20% of Australians meet diagnostic criteria for an alcohol
use disorder. However, only a minority seek professional help due to individual and structural barriers, such as low
health literacy, stigma, geography, service operating hours and wait lists. Telephone-delivered interventions are
readily accessible and ideally placed to overcome these barriers. We will conduct a randomised controlled trial
(RCT) to examine the efficacy of a standalone, structured telephone-delivered intervention to reduce alcohol
consumption, problem severity and related psychological distress among individuals with problem alcohol use.
Methods/design: This is a single site, parallel group, two-arm superiority RCT. We will recruit 344 participants from
across Australia with problem alcohol use. After completing a baseline assessment, participants will be randomly
allocated to receive either the Ready2Change (R2C) intervention (n = 172, four to six sessions of structured telephone-
delivered intervention, R2C self-help resource, guidelines for alcohol consumption and stress management pamphlets)
or the control condition (n = 172, four phone check-ins < 5min, guidelines for alcohol consumption and stress
management pamphlets). Telephone follow-up assessments will occur at 4–6 weeks, 3 months, 6 months and 12
months post-baseline. The primary outcome is the Alcohol Use Disorders Identification Test (AUDIT) score administered
at 3 months post-baseline. Secondary outcomes include change in AUDIT score (6 and 12months post-baseline),
change in number of past-month heavy drinking days, psychological distress, health and wellbeing, quality of life,
client treatment evaluation and cost effectiveness.
Discussion: This study will be one of the first RCTs conducted internationally to examine the impact of a standalone,
structured telephone-delivered intervention to address problem alcohol use and associated psychological morbidity.
The proposed intervention is expected to contribute to the health and wellbeing of individuals who are otherwise
unlikely to seek treatment through mainstream service models, to reduce the burden on specialist services and primary
care providers and to provide an accessible and proportionate response, with resulting cost savings for the health
system and broader community.
Trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12618000828224. Pre-registered on 16 May
2018.
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Background
Alcohol consumption is the second leading cause of pre-
ventable morbidity and mortality in Australia, contribut-
ing to more than 100,000 hospitalisations and 3000 deaths
each year [1] and increasing the risk for more than 60 dif-
ferent diseases and conditions [2]. Almost 50% of Austra-
lians are adversely affected by someone else’s drinking,
costing those around them more than AUD$13 billion in
out-of-pocket expenses and a reduced quality of life esti-
mated at more than AUD$6 billion per annum [3]. Of the
20% of Australians meeting lifetime criteria for alcohol
misuse (i.e. abuse or dependence), only one in five (22.4%)
seeks help [4]. Co-occurring mental health issues, particu-
larly anxiety and mood disorders, are also high [5]. While
publicly funded treatment services are available in each
state and territory, they have necessarily evolved to ad-
dress the complex needs of the comparatively small mi-
nority of dependent drinkers falling at the severe end of
the continuum (i.e. those with significant physical and
mental health comorbidity and marked social disadvan-
tage), often requiring expensive multi-disciplinary and
inter-sectoral care. However, it is the substantially larger
population of problem drinkers without complex medical
or psychosocial needs, who are unlikely to seek treatment,
who cause the greatest cost to society due to their sheer
number [6]. As such, it is imperative that the available
treatment options are broadened to address the entire
continuum of problem alcohol use and that known bar-
riers to treatment accessibility are addressed [7].
There is a substantial body of evidence on the effect-
iveness of brief interventions delivered in primary care
settings for non-treatment-seeking people with problem
alcohol use [8]. Structured, less intensive interventions
can be used within a stepped care model, where individ-
uals commence work on reducing their drinking before
engaging in longer, more intensive programs or treat-
ments, if needed [8]. There is also growing evidence for
the benefit of multi-session brief interventions that typ-
ically address motivation, are solution focused and pro-
vide skills training, goal setting and craving management
strategies [9–11]. Multi-component interventions which
include integrated, evidence-based approaches (e.g. cog-
nitive behavioural therapy and motivational interview-
ing) have been proposed to have an additive effect in
treating problem alcohol use [12] as well as addressing
comorbid mental health problems [9, 10, 13].
Most studies examining the effectiveness of brief inter-
ventions for problem alcohol use have been conducted
in general health settings, particularly primary care,
where problem alcohol use has been identified through
opportunistic screening [14, 15]. Despite the effective-
ness of such interventions, problem alcohol use remains
poorly detected and treated within most healthcare set-
tings [16–18]. Delivery of opportunistic interventions
within primary care is sporadic at best, with multiple
barriers to implementation in these settings (such as
time, cost and lack of knowledge about when and how
to implement such interventions) [19].
Additional barriers to accessing treatment for problem
alcohol use include service accessibility (e.g. wait lists, ser-
vice operating hours and difficulty in attending sessions
scheduled at regular times in fixed locations) [20], geo-
graphical barriers (e.g. location, restricted transport op-
tions and scarcity of services particularly in regional/rural
areas), the experience of self-stigma and concerns about
anonymity. To overcome these barriers, attention has in-
creasingly turned towards designing interventions that
utilise different, flexible and more accessible modes of ser-
vice delivery. Telephone-based support, such as 24/7 alco-
hol and drug helplines, are ideally placed to overcome
many of the barriers to accessing treatment for problem
alcohol use. Alcohol and drug helplines are available in
every Australian state and territory, and they collectively
respond to more than 140,000 calls each year [21]. The
24-h availability of such support offers increased accessi-
bility for individuals in regional areas, as well as those re-
quiring child care, those in full-time employment or those
who feel stigmatised or have a preference for anonymity.
These helplines are often the first point of contact for in-
dividuals seeking help for problem alcohol use. However,
these inbound services traditionally provide a one-off re-
sponse to the caller’s immediate request for assistance,
with a focus on crisis support, information provision and
referral to face-to-face treatment [21, 22].
This study will be one of the first to use randomised
controlled methods to examine the efficacy of standa-
lone, multi-session interventions for problem alcohol
use delivered via telephone, despite evidence for the ef-
fectiveness of telephone-delivered interventions for other
substances (e.g. tobacco and cannabis use) [23, 24]. A re-
cent review of studies, of any methodological design,
that examined telemedicine interventions for the treat-
ment of substance use disorders concluded that this ap-
proach holds potential for effectiveness in reducing
substance use [25]. Despite a paucity of research in the
alcohol field, there is evidence from non-randomised re-
search that proactive telephone-delivered interventions
(i.e. outbound telephone counselling) are likely to be ef-
fective for problem alcohol use [23, 26]. With increasing
support for the effectiveness of telephone-delivered in-
terventions for a range of substance use problems, and
growing concerns related to the increasing harms and
costs associated with problem alcohol use across Austra-
lian communities, we will examine the impact of a
multi-session, structured telephone-delivered interven-
tion (Ready2Change, R2C [27]) to address problem alco-
hol use (and associated psychological morbidity) in a
randomised controlled trial (RCT).
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Choice of comparator
Evidence from primary care settings (and some evidence
from other healthcare settings) suggests that screening
and a single occurrence of brief health education advice
— either verbally or through the provision of self-help
materials — yields short-term improvements in individ-
uals’ alcohol consumption [15, 28, 29]. Data from several
studies suggest that mere exposure to baseline questions
about alcohol use can impact positively on alcohol con-
sumption levels [30]. Baseline questioning effects may
operate through similar mechanisms, prompting reflec-
tion and the self-regulation of behaviour [31]. Still, pool-
ing effect sizes over large numbers of alcohol BI studies
have been able to provide a powerful estimate of how
this form of health promotion performs [15, 30, 32].
Therefore, to control for the effects of alcohol use as-
sessment and frequency of contact, participants in the
control group will receive brief check-in calls and be
provided with health information pamphlets (see Add-
itional file 2: Alcohol consumption pamphlet and Add-
itional file 3: Stress management pamphlet). While
participants in the control condition may experience
some benefit from participation, we expect it will be less
than that obtained for the active condition.
Objectives
The aim of the study is to examine the efficacy of the
R2C telephone-delivered structured intervention in
reducing alcohol problem severity and related psycho-
logical distress in individuals with problem alcohol use
(defined here as an Alcohol Use Disorders Identification
Test (AUDIT) score of > 6 for females and > 7 for males)
[33], compared with the provision of basic health infor-
mation and weekly check-in calls (see Fig. 1).
Trial outcomes
Primary and secondary outcomes for this trial are de-
tailed in Fig. 1.
Methods
Design
This study is a single site, parallel group, two-arm super-
iority RCT, with participants randomly allocated to re-
ceive either the R2C intervention or the control
condition (Fig. 2). The protocol follows Standard Proto-
col Items: Recommendations for Interventional Trials
(SPIRIT) guidelines (see Table 1: SPIRIT figure and Add-
itional file 1: SPIRIT checklist).
Setting
The study is being conducted at Turning Point, a na-
tional addiction treatment and research centre in
Melbourne, Victoria. Turning Point provides a range
of clinical specialist treatment services for people af-
fected by alcohol and other drugs across Australia, in-
cluding a 24-h telephone counselling, information and
referral service.
Fig. 1 Primary and secondary outcomes [34–41]
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Participants
A total of 344 participants (172 participants per trial
arm) will be randomly allocated to one of the two study
conditions.
Inclusion/exclusion criteria
The inclusion and exclusion criteria are described in
Fig. 3.
Recruitment and screening
All assessments will be conducted over the telephone,
using protocols developed in our pilot studies and previ-
ous cohort work [42]. A research assistant (Researcher
1) will perform eligibility assessments and baseline data
collection (see Table 2). A second research assistant (Re-
searcher 2) will perform follow-up data collection. Par-
ticipants, Researcher 2 and the study statistician will
remain blind to participant allocation.
Fig. 2 Study design
Table 1 SPIRIT table
Intervention Follow-up
Screening Baseline R2C Control 4-6 week 3 month Feed-back 6 month 12 month
Contacted by R1 R1 Counsellor R1 R2 R2 R1 R2 R2
Week 0 0 1-6 1-4 4-6 - ~13 - -
Eligibility screen X
AUDIT X X X X
SADQ-C X
SIDAS X
Informed consent X
Allocation X
TLFB X X X X X
Substance use X X X X
K10 X X X X
EUROHIS-QOL 8-item index X X X X
Adverse events X X X X X X X X
Barriers to help-seeking X
Additional treatment enquiry X X X X
AQoL-6D X X X X
WHO HPQ X X X X
Cost data X X X X
Counselling sessions X
Self-help resources X
Information pamphlets X X
CEST X
Qualitative feedback X
R1 Researcher 1, R2 Researcher 2
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To recruit our target sample size, recruitment methods
will be broad. Participants will be recruited from across
Australia via a number of channels, including print, radio
and online advertising (including social media), clinician re-
ferrals, helpline service referrals (i.e. interstate Alcohol and
Drug Information Services that do not currently offer R2C-
type outbound interventions) and opportunistic study pro-
motion. Online advertising will be the primary recruitment
strategy due to its broad reach and cost effectiveness [43].
In the case of online advertising, individuals will be linked
to a secure Qualtrics form in which to enter their contact
details. Individuals who express interest in participating will
be called by Researcher 1 and verbally provided with de-
tailed information about the study before being assessed for
eligibility to participate. Those who are eligible will be pro-
vided with the Participant Information and Consent Form
(PICF) and asked to provide verbal consent to participate
by Researcher 1. Baseline data collection can be undertaken
during this phone call or scheduled for a different time as
preferred by the participant. Participants will be rando-
mised on completion of the baseline assessment.
Randomisation
Participants will be randomly assigned to the R2C group
or the control group with a 1:1 allocation ratio. Ran-
domisation will be stratified by gender and will use a
standard computer-generated “permuted blocks of vari-
able size” scheme for each stratum. Randomisation lists
for each stratum will be generated at the start of the
study by the study statistician and linked to a unique
identification code. The statistician who prepares the
lists will play no other role in the delivery of the inter-
ventions. Allocations will be concealed in individual enve-
lopes labelled with the unique identification code and
opened (in consecutive order) by the designated researcher
(Researcher 1) after the baseline assessment. Envelopes
were used because at the time of trial design and start-up it
was not feasible to implement a centrally managed, online
randomisation system. The contents of an envelope cannot
be discerned without opening the envelope, and monitoring
of randomisation dates and within-stratum sequence num-
bers is conducted to ensure randomisation errors do not
occur. Randomised participants will be assigned their
unique identification code, which will be in a re-identifiable
format. Participants’ identifying information collected dur-
ing this study will be stored separately from trial data, while
the unique identifying code will be attached to both. Partici-
pant information and trial data will be stored in separate
locked filing cabinets located on the study premises.
Following randomisation, participants will be con-
tacted by Researcher 1 and provided with an overview of
their assigned protocol (i.e. R2C or control). Participants
will not be told any details about the other intervention.
Appropriate resources will be sent to the participant
(R2C intervention: R2C self-help booklets [44, 45] +
pamphlets [34, 46]; control: pamphlets [34, 46]). Hard
copy materials will be posted to the participant (soft
copy materials will be sent via email at the participants’
preference). An outbound telephone call will be sched-
uled within 7 days to commence the four to six R2C ses-
sions with the participant’s dedicated R2C Counsellor
(intervention), or to commence the four phone check-ins
with Researcher 1 (control). The treatment period starts
within 7 days of randomisation.
Intervention
Participants randomised to the R2C intervention will
receive telephone counselling (incorporating evi-
dence-based interventions [47–50]), self-help re-
sources and pamphlets (Fig. 4).
Participants randomised to the control conditions will
receive pamphlets and telephone contacts (Fig. 5).
In both the treatment and control conditions, the call
duration will be recorded. Short Message Service (SMS)
messages will be sent to remind participants of all pre-
arranged telephone sessions, and five attempts at contact
within 1 week will be made per scheduled phone session.
R2C intervention calls will be made from Turning
Fig. 3 Participation criteria
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Table 2 Trial measures
Data collected Method
Screening measures Demographic
information
Structured questions
Standard demographic characteristics (e.g. age, gender, education level)
Problem alcohol use
AUDIT
Assessed by the Alcohol Use Disorders Identification Test (AUDIT) [33]. A score of > 6 for
women and > 7 for men warrants inclusion in the study
Severity of alcohol
dependence
SADQ-C
Assessed by the Severity of Alcohol Dependence Questionnaire (SADQ-C) [54]. A score of 31
or higher indicates “severe alcohol dependence” and warrants exclusion from the study
Presence/severity of
suicidal thoughts
SIDAS
Assessed by the Suicidal Ideation Attributes Scale (SIDAS) [55]. A score of 21+ indicates high
risk of suicidal behaviour and warrants exclusion from the study
Other inclusion/
exclusion
Structured questions
Structured questions querying self-reported information pertaining to the study’s inclusion/ex-
clusion criteria (e.g. history of psychosis)
Outcome measures
Primary outcome Alcohol problem severity
AUDIT
The primary outcome is alcohol problem severity at 3 months, assessed by the AUDIT. The
time frame has been adapted to cover month prior to assessment (rather than year), so that
planned follow-up assessments at 3, 6 and 12 months can be performed. Five short items from
the recent Australian Institute of Health and Welfare (AIHW) National Drug Strategy Household
Survey have been included to provide additional information on self-reported change in alco-
hol use and alcohol literacy
Secondary outcomes Alcohol use patterns
TLFB
Past-month (30 days) alcohol consumption and heavy drinking days, assessed by the Alcohol
Timeline Follow-back (TLFB) [35]. Heavy drinking days are measured as > 40/60 g of alcohol (4/
6 standard drinks)
Substance use
AOD Self-Completion
Form
Assessed using items from the Victorian Department of Health and Human Services (DHHS)
Victorian AOD Self-Completion Form [56], recording recent use of other drugs and frequency
of use in the past 28 days
Psychological distress
K10
Assessed by the Kessler Psychological Distress Scale (K10) [36]
Quality of life
EUROHIS-QOL 8-item
index
AQoL-6D
Assessed by the EUROHIS-QOL 8-item index [37, 57] and Assessment of Quality of Life (AQoL-
6D) [38]
Cost effectiveness
AQoL-6D
WHO HPQ
Health-care Resource Use
Questionnaire
The incremental cost of treatment will be compared to the incremental benefits of treatment
in terms of the primary outcomes and the difference in quality-adjusted life years (QALYs;
assessed by the AQoL-6D). Work performance and productivity will be assessed by items from
the WHO Health and Work Performance Questionnaire short form (WHO HPQ) [40]. Healthcare
resource use is assessed using items from the 3Mg trial’s Health-care Resource Use Question-
naire [41]
Adverse events
Structured questions
During baseline, scheduled intervention/control calls, and follow-up calls, participants will be
asked general questions: “Have you had any health concerns recently (baseline)/since the last
time you had telephone contact for this study?”, “Have you felt unwell or different since the last
time you had telephone contact for this study?” and “Do you have any specific worries or com-
plaints about your health in general?”, as well as more specific questions: “Has your alcohol use
changed?” and “Has your mood changed?”
Additional measures/
participant feedback
Barriers to help-seeking
Structured questions
Perceived barriers to treatment-seeking for alcohol problems will be identified through an
open-ended question (“What are the reasons that you have not sought treatment for your alco-
hol use in the past?”) and from a list of 15 barriers (e.g. financial, stigma, readiness for change)
developed by Schuler et al. [58]
Treatment participation
and satisfaction
CEST TCU ENG
Assessed by the Client Evaluation of Self and Treatment (CEST) short form (TCU ENG) [39]
(approximately 20% of the R2C intervention group)
Qualitative feedback
Structured questions
Questions asked will include: “Which parts, if any, of the telephone intervention sessions were
most helpful to you? How were these most helpful?” and “What did you think about the delivery,
format and duration of the telephone intervention sessions?” (approximately 20% of the R2C
intervention group)
Additional treatment
enquiry
Structured questions
Engagement in any additional treatment (e.g. inpatient/outpatient treatment) or mutual aid
group attendance (AA, SMART Recovery) will be queried and recorded for all participants
(exclusion criterion at screening only)
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Fig. 4 R2C intervention [27, 42, 44, 45, 47–50]
Fig. 5 Control condition
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Point’s telephone and online services department, which
is equipped with the infrastructure needed for outbound
calls and call recording.
Follow-up
Follow-up assessments will be conducted by Researcher
2. The first follow-up assessment will be performed at
4–6 weeks post-baseline. Follow-up assessments will also
be performed at 3, 6 and 12 months. The assessment at
4–6 weeks post-baseline will take approximately 10 min
to complete (Timeline Follow-back [TLFB], adverse
events and additional treatment enquiry only). The next
three follow-up assessments will take approximately 30
min to complete. For each follow-up, five attempts to
contact the participant will be made within 2 weeks. Ap-
proximately 20% of the intervention group, selected
using random start systematic sampling, will be asked to
complete additional qualitative feedback post the 3
months follow-up.
Loss to follow-up
Participants who cannot be contacted after five phone
calls will be deemed to be missing at that data collection
time point. Researcher 2 will attempt to contact partici-
pants again at the next data collection time point, fol-
lowing the same procedure, unless the participant
actively withdraws.
Retention
The study will use retention enhancement techniques sug-
gested by previous studies [51, 52] to encourage retention
in the intervention calls and follow-up assessments. Re-
tention enhancement techniques will include active verbal
commitment, flexibility in scheduled call times, weighting
reimbursements according to the importance of collecting
data at each time point and text message reminders before
scheduled calls.
Reimbursement
Participants will be reimbursed with vouchers as follows:
AUD$20 for baseline assessment, AUD$20 for 4–6weeks
assessment, AUD$40 for 3months assessment (primary
outcome time point), AUD$20 for 6months assessment,
AUD$40 for 12months assessment (last assessment) and
AUD$10 for treatment evaluation/qualitative feedback (for
those who are selected).
Data collection
An electronic Case Report Form (eCRF) will be com-
pleted for each participant using REDCap (Research
Electronic Data Capture [53]), summarising all screening
and study data. REDCap is a secure, web-based applica-
tion designed to support data capture for research
studies (including case report forms, real-time data entry
validation and audit trails).
Trial monitoring
Treatment integrity
Training and supervision to ensure treatment fidelity
will include a week-long training session focusing on
competence and adherence to the R2C intervention and
research procedures, as well as regular clinical supervi-
sion. All sessions will be digitally recorded, and an inde-
pendent research assistant will rate fidelity of
intervention sessions for 20% of participants using ran-
dom start systematic sampling. During each intervention
session, R2C Counsellors will complete a checklist of
modules, exercises and homework activities completed,
to assist with adherence with the intervention.
Training will be provided to Researcher 1 (who com-
pletes the control group telephone check-ins), and a
script will be used to ensure that only past-week use of
pamphlets is queried (i.e. no inadvertent individualised
counselling). Supervision of Researcher 1 will occur to
prevent “drift”, and call duration records will be checked
intermittently.
Adverse events
All adverse events will be recorded between the time
of consent and the final follow-up visit. Participants
will be asked about adverse events at baseline, during
each R2C session/control check-in and at each point
of follow-up contact. Participants will also be encour-
aged to contact the research team if they are con-
cerned about an adverse event.
Participant assessed as at risk of suicide
When a participant is assessed as being at high risk of sui-
cidal behaviour (a Suicidal Ideation Attributes Scale
[SIDAS] score of 21+), referral to appropriate support is
immediate. Researchers are trained in the National Centre
for Suicide Prevention Training two-day Applied Suicide
Intervention Skills Training (ASIST) course to ensure they
are equipped with the skills to respond to suicide risk. Re-
searchers are trained to transfer the participant to an on-
duty Turning Point helpline counsellor when immediate
risk is identified in order for risk to be managed and
responded to in accordance with the clinical service’s clin-
ical protocol. R2C Counsellors are well trained and experi-
enced in the management of suicide risk, and clinical
governance of risk for the trial is managed in accordance
with organisational risk management procedures.
Participant withdrawal/discontinuation
The right to withdraw without consequence is outlined
during the consent process and in the PICF. Verbal
revocation of consent can be provided by the participant,
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or a Revocation of Consent form can be completed, with
the option to remove all of the participant’s previously
collected data or just to remove consent for further data
collection. No further contact with the participant will
be initiated by the research team upon verbal or written
revocation of consent.
In instances where it has been identified that a partici-
pant meets exclusion criteria during the study (e.g. active
suicidality), and/or that it is not in the best interests of
the participant to remain in the study, the Principal In-
vestigator (a psychiatrist) will decide whether to with-
draw the participant from the trial. If a participant is
withdrawn by the Principal Investigator, the reasoning
for this will be explained to the participant. The partici-
pant will be referred to the appropriate clinical services
for treatment and support. No further data collection
will occur, with the exception of the details regarding ad-
verse events.
Statistical methods
Sample size estimation
A pilot study of an earlier version of the telephone-
delivered intervention examined outcomes to a 3 month
follow-up [42]. Thirty-four individuals concerned about
their drinking were referred to the program and com-
pleted an average of 5.5 sessions. Participation in the
intervention demonstrated significant reduction in alco-
hol problem severity (AUDIT score) and improvement
in psychological distress (Kessler Psychological Distress
Scale [K10] score). Treatment satisfaction and counsellor
rapport scores were comparable to those found in face-
to-face treatment. Using data from the pilot work, we
found that the between-subject variance component in
the AUDIT score was 23.8, the within-subject variance
component was 49.8 (intraclass correlation [ICC] =
0.323) and the estimated improvement (decline) in the
AUDIT score was 11.2 (standard error [SE] = 1.69). The
calculation of the sample size used these estimates of the
variance components, from the single-arm pilot study, and
was based on the power of the F test for the overall time by
treatment arm interaction and the power of the t test for
the interaction contrast of primary interest, namely, base-
line versus 3months by treatment arm; calculations used
the “apower” procedure for the non-central F distribution,
and the “cut” function for the non-central t distribution in
the GenStat statistical package [59].
We estimate, conservatively, that by 3 months, there
will be an improvement (reduction of at least 8 on the
AUDIT score) in the R2C arm and that the control arm
could exhibit a modest improvement of 4. If these im-
provements are sustained at 6 and 12months, then with
120 evaluable subjects in each arm and assuming inde-
pendence between subjects and equicorrelation within
subjects, the F test, conducted at the 5% significance
level, for this treatment-by-time interaction will have
90% power (and the two-sided, 5% level, t test for the
interaction contrast at 3 months will have 85% power). If
these conjectured improvements by 3 months are not
durable and, for example, deteriorate by 50% at 6
months, and the scores return, on average, to their base-
line levels at 12 months, then this treatment-by-time
interaction scenario will be detected with 85% power,
and the power of the two-sided, 5% level t test for the
interaction contrast at 3 months (the analysis of the pri-
mary outcome) remains unchanged at 85%.
The target sample size has been inflated from 120 per
arm to 172 per arm to allow for approximately 30%
drop-out, which is based on the attrition rate reported
in a Swedish helpline study [26] and the experiences of
the Chief Investigators where attrition in trials of face-
to-face psychosocial interventions with this population
average around 20% at 12months [13].
Statistical analysis plan
Data will be collated, cleaned and validated, using pro-
grammed edit checks, in a database that will be locked
prior to the unblinding of the study statistician. The pri-
mary analysis will take place after all subjects, not
known to have withdrawn or not deemed lost to follow-
up, have had their 12 months assessments, based on the
intention-to-treat principle (i.e. subjects’ data are ana-
lysed as randomised and as stratified). A “per-protocol”
sensitivity analysis will be restricted to those subjects
with at least one post-baseline assessment and, for sub-
jects randomised to the R2C arm, participation in at
least one structured telephone counselling session.
The repeated measurements of the outcome variables
will be analysed by fitting linear mixed models, with
fixed effects for treatment and time, and their inter-
action, and random effects for subjects and assessments
within subjects, using restricted maximum likelihood
(REML). As well as accommodating missing values
under the missing at random assumption, this method
will allow the most suitable variance-covariance model
for the repeated measures to be selected, using Akaike’s
information criterion [63], and commonality of nonlin-
ear trends over time to be explored via splines. The F
test will be used to test for an overall group-by-time
interaction, and the primary comparison, between
groups, of their changes from baseline to 3months
follow-up will be based on a t test of the corresponding
interaction contrast — this t test will utilise the pre-
dicted means and their variance-covariance matrix that
are recovered from the fitted mixed model. Diagnostic
plots of residuals will be assessed and, if deemed neces-
sary, variance-stabilising transformations, such as the
empirical logistic transformation, will be applied to the
outcome variables and inferences will be based on the
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analyses conducted on the transformed scale. In a series
of exploratory analyses, mixed models with covariates
for gender, illicit drug use, extent of exposure to the
intervention, exposure to other treatments or programs,
level of psychological distress and, as appropriate, level
of alcohol use at baseline will be fitted, including their
interactions with treatment group, in order to identify
moderating factors. A sensitivity analysis, to assess the
impact of missing 3-month data on the primary out-
come, will use a “tipping point” approach [63]. Categor-
ical, ordinal and binary outcomes will be analysed in a
similar way using generalised linear mixed models
(GLMMs). The complete list of candidate covariates and
details of the analyses will be specified in a statistical
analysis plan that will be reviewed and approved by the
Principal Investigator prior to database lock. Analyses
will be conducted using the most appropriate procedures
in GenStat, R and STATA.
Cost effectiveness
Economic evaluation will assess the incremental cost of
R2C compared to the control. The incremental cost will
be compared to the incremental benefits of treatment in
terms of the primary outcomes and the difference in
quality-adjusted life years (QALYs). The incremental
QALYs will be measured by the between-group differ-
ence in the mean Assessment of Quality of Life – 6D
(AQoL-6D) score over 12 months. A social perspective
on costs will be taken and will include resource use in-
curred in the delivery of the helplines as well as health
services irrespective of payment source. Healthcare costs
will be calculated from the utilisation data and average
unit costs for each item. Running but not training costs
will be included in the primary analysis. The inclusion of
time/productivity gains is controversial, and the cost-
effectiveness ratios will be calculated with and without
these “indirect costs” in the primary analysis, but a sec-
ondary analysis will include the money value of time lost
from work and from lower productivity while at work
using the World Health Organization (WHO) Health
and Work Performance Questionnaire (HPQ). Confi-
dence intervals for incremental cost effectiveness will be
calculated directly using non-parametric bootstrapping.
In addition, we will calculate a cost-effectiveness accept-
ability curve for a range of hypothetical money values of
outcomes, based on individual cost and outcome differ-
ences between groups over the 12months, using mixed
linear regression modelling adjusted for baseline values
of outcome and gender.
Dissemination and translation plan
The results of this trial will be disseminated to academic
and health professional audiences via peer-reviewed pub-
lications and conference presentations. Participants will
be informed they can access the Turning Point website
for a summary report of trial findings in 2020. We will
provide the results to the public via a press release and
relevant sector newsletters. The outcomes of this re-
search are expected to inform policy development by
providing evidence of a practical, low-cost population-
level approach to reduce problem alcohol use. The trial
results will also be communicated to policymakers with
the aim of implementing the program nationally (R2C is
currently available in Victoria, Australia).
Discussion
The outcomes of this project are expected to make a sig-
nificant contribution to the health and wellbeing of Aus-
tralians who are otherwise unlikely to seek treatment
from specialist services, as well as generate substantial
cost savings for the health system and broader commu-
nity. Given that the proposed telephone-delivered model
has already been piloted within an existing helpline ser-
vice, we expect the feasibility of the proposed study to
be high. Co-location between the research team and an
existing national treatment service is a major strength of
this study. This allows for close monitoring of study
protocol adherence and for immediate feedback be-
tween the research team and counsellors. With a
research-to-practice gap evident in translational health
research, and a significant lag time between imple-
mentation of treatments shown to be effective in re-
search (up to 15 years), this co-location also provides
a unique opportunity to allow the findings to be
quickly disseminated and implemented.
The study addresses the ethical issue of clinical equi-
poise. There is evidence to suggest that “ultra-brief”
single-session interventions are effective in reducing
problem alcohol use [60], which may be as little as the
provision of information pamphlets [61], monitoring
[62] or asking about one’s alcohol use [31]. There is cur-
rently uncertainty around the relative benefit of the ex-
tended R2C intervention, although it is expected that
this multi-session model will result in improved out-
comes. Additionally, although current engagement in
treatment/intent to seek treatment is an exclusion criter-
ion for the study, participants are not prohibited from
seeking treatment after enrolment. Given that partici-
pants will receive detailed assessment, information pam-
phlets, monitoring for adverse events throughout the
study and provision of referral information where neces-
sary (i.e. appropriate helplines or advice to speak with a
general practitioner), it is possible that participants ran-
domised to the control group will still receive a standard
of care that may assist them to reduce their alcohol
consumption.
This will be one of the first RCTs internationally to
examine the efficacy of a standalone telephone-delivered
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intervention for problem alcohol use. The outcomes of
this study are likely to inform the delivery of interven-
tions for a range of other health conditions, particularly
those where help-seeking is low, stigma is high or early
intervention is a priority (e.g. illicit drug use, gambling,
mental health problems). The proposed model being
tested has the potential to reduce the burden on spe-
cialist addiction treatment services and provide a
more appropriate and proportionate response to prob-
lem alcohol use. The model also provides potential
for significant cost savings by intervening before pro-
gression to a greater severity or chronicity of problem
alcohol use.
Trial status
This trial is at protocol version 4, dated 27 February
2018. Recruitment commenced on 25 May 2018. To
date, 285 participants have been randomised. Recruit-
ment of participants is expected to be completed by No-
vember 2019 (with the last 12 months follow-up to be
completed in November 2020).
Additional files
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
Additional file 2: Alcohol Consumption Pamphlet. (PDF 245 kb)
Additional file 3: Stress Management Pamphlet. (PDF 113 kb)
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